問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others--

Division of General Internal Medicine

Division of General Internal Medicine

Taichung Veterans General Hospital

Division of Cardiovascular Diseases

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

CHANGHUA CHRISTIAN HOSPITAL

Division of Hematology & Oncology

更新時間：2023-09-19

吳尚儒Wu, Shang-Ju
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

89Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚儒

List

150Cases

2010-11-01 - 2021-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2010-12-01 - 2018-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2024-09-16 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-06-01 - 2028-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-07-14 - 2026-11-30

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-02-19 - 2025-12-31

Phase I

Completed
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL

  • Condition/Disease

    Non-Hodgkin Lymphoma/Chronic lymphoid leukemia

  • Test Drug

    JNJ-75348780

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2025-03-01 - 2028-04-30

Phase I

Active
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    皮下注射劑 膠囊劑

Participate Sites
4Sites

Recruiting4Sites

2013-03-01 - 2019-10-31

Phase III

Completed
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

  • Condition/Disease

    Mantle Cell Lymphoma

  • Test Drug

    Ibrutinib

Participate Sites
6Sites

Terminated6Sites

2023-12-01 - 2027-03-01

Phase I/II

Active
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

  • Condition/Disease

    B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Test Drug

    AZD0486

Participate Sites
5Sites

Recruiting5Sites

2019-05-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3 4 5 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB